English | Español

Merck & Company, Inc.
Bree Gonzales | Feb 2, 2022

Molnupiravir is now the last choice for COVID-19: 'The Merck product is only 30% effective'
Press release submission | Sep 23, 2019

MERCK: New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care

Trending
+ Pharmaceuticals
Patient Daily | May 28, 2025

University of California medical researcher: ‘The 340B program is not associated with an improvement in mortality for low-income patients'
+ Pharmaceuticals
Patient Daily | May 29, 2025

Executive director of COA on 340B reform: ‘Start with PBMs then mega hospitals that pocket 340B discounts’
+ Pharmaceuticals
Patient Daily | Jun 2, 2025

PathAI collaborates with Northwestern Medicine on digital pathology advancements
+ Pharmaceuticals
Patient Daily | May 27, 2025

New study shows effectiveness of recent RSV prevention strategies